Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma

Johnson, David; B.Y., Brigette

doi:10.1016/j.oraloncology.2020.105127

Cited by 29 publications

(21 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It seems confident to say that shrinkage of tumors invading left atrium with intensive systemic chemotherapy should also be the first step of treatment prior to surgical procedures of curative intent for chemotherapy-sensitive metastasis from other primary sites including nasopharyngeal carcinoma. Furthermore, in the era of molecular targeted therapy and immunotherapy, in addition to immune checkpoint inhibitors [16], rapid progress could be expected in the field of developing specific therapeutic agents targeting Epstein-Barr virus-related molecules [17][18], probably rendering invasive resection of even less priority in treating metastatic nasopharyngeal carcinoma a few years from now.…”

Section: Discussionmentioning

confidence: 99%

Remarkable Response to Cisplatin Doublet Chemotherapy in Pulmonary Metastasis With Left Atrial Extension From a Nasopharyngeal Cancer

Fan¹,

Chiu²,

Huang³

et al. 2021

Cureus

View full text Add to dashboard Cite

A 60-year-old male patient whose nasopharyngeal carcinoma was brought to complete remission with induction chemotherapy composing of cisplatin plus fluorouracil and subsequent radiotherapy with intent of cure eight years ago presented with dyspnea due to left side massive pleural effusion with pleural seedings, left lower lobe huge space occupying lesion, and left atrial tumor extending from the intrapulmonary lesion through left inferior pulmonary veins. Pleural biopsy revealed a picture of nonkeratinizing squamous cell carcinoma positive for Epstein-Barr virus-encoded small RNAs in situ hybridization, leading to a diagnosis of late pulmonary metastases from the antecedent nasopharyngeal carcinoma. Systemic chemotherapy with initial cisplatin plus paclitaxel and subsequent cisplatin plus gemcitabine brought remarkable resolution to the malignant cardiac and intrathoracic lesions. So far as we know, this is the first case report of left atrial invasion from pulmonary metastasis of a nasopharyngeal carcinoma origin in the English literature.

show abstract

Section: Discussionmentioning

confidence: 99%

Remarkable Response to Cisplatin Doublet Chemotherapy in Pulmonary Metastasis With Left Atrial Extension From a Nasopharyngeal Cancer

Fan¹,

Chiu²,

Huang³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…The interaction of the PD-1 (programmed cell death-1 receptor) for its ligand PD-L1 allows tumor cells to escape immune surveillance. The paradigm based on the inhibition of immune checkpoints PD-1/PD-L1 has been approved as a standard of treatment for non-small cell lung cancer (NSCLC) [ 86 ] and for other neoplasms [ 87 , 88 ]. In the last decade, several anti-PD-1/PD-L1 monoclonal antibodies have been approved, and an increasing number of peptide and non-peptide small molecule inhibitors have been discovered.…”

Section: Targeting Clinically Significant Ppis With Interfacial Peptidesmentioning

confidence: 99%

Interfacial Peptides as Affinity Modulating Agents of Protein-Protein Interactions

2022

View full text Add to dashboard Cite

The identification of disease-related protein-protein interactions (PPIs) creates objective conditions for their pharmacological modulation. The contact area (interfaces) of the vast majority of PPIs has some features, such as geometrical and biochemical complementarities, “hot spots”, as well as an extremely low mutation rate that give us key knowledge to influence these PPIs. Exogenous regulation of PPIs is aimed at both inhibiting the assembly and/or destabilization of protein complexes. Often, the design of such modulators is associated with some specific problems in targeted delivery, cell penetration and proteolytic stability, as well as selective binding to cellular targets. Recent progress in interfacial peptide design has been achieved in solving all these difficulties and has provided a good efficiency in preclinical models (in vitro and in vivo). The most promising peptide-containing therapeutic formulations are under investigation in clinical trials. In this review, we update the current state-of-the-art in the field of interfacial peptides as potent modulators of a number of disease-related PPIs. Over the past years, the scientific interest has been focused on following clinically significant heterodimeric PPIs MDM2/p53, PD-1/PD-L1, HIF/HIF, NRF2/KEAP1, RbAp48/MTA1, HSP90/CDC37, BIRC5/CRM1, BIRC5/XIAP, YAP/TAZ–TEAD, TWEAK/FN14, Bcl-2/Bax, YY1/AKT, CD40/CD40L and MINT2/APP.

show abstract

“…Indeed, PD-1 and PD-L1 are expressed in many EBV-positive cancers, such as HL, PTLD, DLBCL, NPC, GC, and NKTCL, as well as chronic active Epstein-Barr virus infection (CAEBV), and in infiltrating immune cells [31][32][33][34][35][36][37][38][39][40][41]. PD-1/PD-L1 inhibitor products have already been approved or shown to have marked efficacy for treatment of several cancers, including HL, NKTCL, NPC, and GC [42][43][44][45][46][47]. EBV induces PD-L1 expression through multiple mechanisms (Figure 1).…”

Section: Ebvmentioning

confidence: 99%

Human Herpesvirus and the Immune Checkpoint PD-1/PD-L1 Pathway: Disorders and Strategies for Survival

Murata

2021

Microorganisms

View full text Add to dashboard Cite

The immune system has evolved as a complex and efficient means of coping with extrinsic materials, such as pathogens and toxins, as well as intrinsic abnormalities, such as cancers. Although rapid and timely activation of the immune system is obviously important, regulated downregulation of the system is almost as significant as activation to prevent runaway immunity, such as allergies and hypercytokinemia. Therefore, the immune checkpoint programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway is beneficial for the host. On the other hand, pathogens have evolved to evade host immunity by taking advantage of the PD-1/PD-L1 pathway. This review is focused on human herpesviruses, such as herpes simplex virus (HSV), cytomegalovirus (CMV), and Epstein–Barr virus (EBV), which cause various types of disorders, and their relationships with the PD-1/PD-L1 pathway. Understanding such relationships will be useful for developing preventative and therapeutic methods for disorders caused by herpesviruses.

show abstract

Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma

Cited by 29 publications

References 49 publications

Remarkable Response to Cisplatin Doublet Chemotherapy in Pulmonary Metastasis With Left Atrial Extension From a Nasopharyngeal Cancer

Remarkable Response to Cisplatin Doublet Chemotherapy in Pulmonary Metastasis With Left Atrial Extension From a Nasopharyngeal Cancer

Interfacial Peptides as Affinity Modulating Agents of Protein-Protein Interactions

Human Herpesvirus and the Immune Checkpoint PD-1/PD-L1 Pathway: Disorders and Strategies for Survival

Contact Info

Product

Resources

About